Most Recent

image: Fecal Transplant Pill Fails Trial

Fecal Transplant Pill Fails Trial

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

2 Comments

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: Cullen Buie Parses Pathogens With Passion

Cullen Buie Parses Pathogens With Passion

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

1 Comment

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: Riboswitch Screen

Riboswitch Screen

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: Wanted: Transcriptional Regulators

Wanted: Transcriptional Regulators

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: Classic Example of Symbiosis Revised

Classic Example of Symbiosis Revised

By | July 25, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: Donor-Soil Microbes Drive Ecosystem Restoration

Donor-Soil Microbes Drive Ecosystem Restoration

By | July 11, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

5 Comments

image: A New Role for Marine Archaea

A New Role for Marine Archaea

By | July 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: Archaea’s Role in Carbon Cycle

Archaea’s Role in Carbon Cycle

By | July 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech